These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22410678)

  • 21. Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.
    Djavan B
    Eur Urol; 2010 Jun; 57(6):928-9. PubMed ID: 20304552
    [No Abstract]   [Full Text] [Related]  

  • 22. Prostate cancer screening--the evidence, the recommendations, and the clinical implications.
    Chou R; LeFevre ML
    JAMA; 2011 Dec; 306(24):2721-2. PubMed ID: 22203543
    [No Abstract]   [Full Text] [Related]  

  • 23. Prostate cancer screening: a complicated puzzle, explanation needed.
    Gaster B
    J Gen Intern Med; 2013 Dec; 28(12):1549-50. PubMed ID: 23824908
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate cancer screening with prostate-specific antigen testing: more answers or more confusion?
    Diamandis EP
    Clin Chem; 2010 Mar; 56(3):345-51. PubMed ID: 20093554
    [No Abstract]   [Full Text] [Related]  

  • 25. Benefits and pitfalls of prostate cancer screening: "no proof of benefit" does not equal "proof of no benefit".
    Chen CP; Staggers FE; Roach M
    Oncology (Williston Park); 2011 May; 25(6):466, 468. PubMed ID: 21717899
    [No Abstract]   [Full Text] [Related]  

  • 26. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.
    Tikkinen KAO; Dahm P; Lytvyn L; Heen AF; Vernooij RWM; Siemieniuk RAC; Wheeler R; Vaughan B; Fobuzi AC; Blanker MH; Junod N; Sommer J; Stirnemann J; Yoshimura M; Auer R; MacDonald H; Guyatt G; Vandvik PO; Agoritsas T
    BMJ; 2018 Sep; 362():k3581. PubMed ID: 30185545
    [No Abstract]   [Full Text] [Related]  

  • 27. Future of screening for prostate cancer.
    Dahm P
    BMJ; 2017 Sep; 358():j4200. PubMed ID: 28928226
    [No Abstract]   [Full Text] [Related]  

  • 28. Prostate cancer: PSA velocity in prostate cancer screening--the debate continues.
    Borofsky MS; Makarov DV
    Nat Rev Urol; 2011 Jul; 8(8):413-4. PubMed ID: 21750502
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate cancer: Draft USPSTF 2017 recommendation on PSA testing - a sea-change?
    Van der Kwast TH; Roobol MJ
    Nat Rev Urol; 2017 Aug; 14(8):457-458. PubMed ID: 28607501
    [No Abstract]   [Full Text] [Related]  

  • 30. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
    Ito K
    Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
    [No Abstract]   [Full Text] [Related]  

  • 31. Prostate-specific antigen: a new(ish) study.
    Harv Mens Health Watch; 2010 Nov; 15(4):6-8. PubMed ID: 21166115
    [No Abstract]   [Full Text] [Related]  

  • 32. Prostate cancer: estimating the benefits of PSA screening.
    Vickers AJ; Lilja H
    Nat Rev Urol; 2009 Jun; 6(6):301-3. PubMed ID: 19498406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer screening: and yet it moves!
    Kwiatkowski M; Randazzo M; Kluth L; Manka L; Huber A; Recker F
    Asian J Androl; 2015; 17(3):437-8. PubMed ID: 25532573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Screening for prostate cancer: an up date].
    Ito K
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):33-7. PubMed ID: 22241351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
    Black A; Berg CD
    Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Changes in Prostate Cancer Screening Practices and Epidemiology.
    Lee DJ; Mallin K; Graves AJ; Chang SS; Penson DF; Resnick MJ; Barocas DA
    J Urol; 2017 Dec; 198(6):1230-1240. PubMed ID: 28552708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in Prostate-Specific Antigen Screening and Prostate Cancer Interventions 3 Years After the U.S. Preventive Services Task Force Recommendation.
    Ong MS; Mandl KD
    Ann Intern Med; 2017 Mar; 166(6):451-452. PubMed ID: 28320011
    [No Abstract]   [Full Text] [Related]  

  • 38. PSA testing and early management of test-detected prostate cancer--consensus at last.
    Lawrentschuk N
    BJU Int; 2016 Apr; 117 Suppl 4():5-6. PubMed ID: 27094969
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Terris MK
    Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530
    [No Abstract]   [Full Text] [Related]  

  • 40. Perspective on...the new PSA screening recommendations.
    Marsland T; Arena F; Yeilding A; Glodé M; Ellis L; Yu J; Henderson C; Wagman L; Piver S; Minsky B; Rosen S; Poplack D; Potters L; Crawford D; Hoskins W
    Oncology (Williston Park); 2011 Nov; 25(12):1183, 1187-8, 1190. PubMed ID: 22229211
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.